Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

KPV Research Guide: Three Residues, Transporters, and Gut Models

KPV is a three-residue peptide with a research story shaped by cellular uptake and delivery. Here is how to read the intestinal-model studies without losing those distinctions.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Compound Lys-Pro-Val; KPV
Molecule class Tripeptide
Research themes PepT1 transport and preclinical intestinal inflammation models
Hero catalog sizes 5 mg and 10 mg
Evidence distinction Free peptide and engineered delivery systems are different test articles
Hero product KPV

KPV stands for lysine-proline-valine, a three-residue peptide investigated in inflammation research. Its small size makes the name easy to remember, but the experimental story is more specific: how the peptide reaches a cell, what that cell expresses, and how the resulting response is measured.

Hero’s supplied export lists KPV in 5 mg and 10 mg formats. The most useful background is the connection between PepT1-mediated uptake, intestinal-model studies, and engineered delivery systems that should not be mistaken for free peptide.

What KPV is: the sequence is only the starting point

Dalmasso and colleagues identified KPV as the Lys-Pro-Val tripeptide in their 2008 intestinal-inflammation study. The defined sequence gives researchers a specific test article to investigate, but its response still depends on the experimental system (Dalmasso et al., 2008).

Three residues do not eliminate the need for identity checks. The sequence, terminal chemistry, supplied form, and stated quantity basis should match the intended method. A name on a vial does not answer every question about the sample used in an experiment.

KPV also should not inherit findings from an unrelated peptide merely because both appear in gut-research discussions. For comparison, the BPC-157 research guide concerns a different molecule and literature. A shared research topic does not create a shared mechanism or establish that the materials work together.

How KPV research connects uptake with inflammatory signaling

The 2008 Dalmasso study examined the peptide transporter PepT1 in intestinal epithelial and immune-cell systems. It linked transporter-mediated KPV uptake with changes in inflammatory signaling, including NF-κB and MAP kinase-related measurements. The authors also studied chemically induced colitis models in mice (Dalmasso et al., 2008).

That combination is informative because it asks both how a compound enters a relevant system and what happens downstream. It still leaves separate questions about how well the model represents a particular human disease and whether the same exposure can be achieved in another setting.

For experimental design, the transporter is therefore part of the question. A response in one cell line should not be assumed in a second line without checking the biological context. A study that measures uptake and signaling can support a more specific interpretation than one reporting only a final change.

What the KPV studies measured

Later work investigated ways to deliver KPV to an intestinal target. Those studies add an important variable: the formulation itself.

Study Test system Research contribution Interpretation limit
Dalmasso et al., 2008 Cell systems and mouse colitis models Examined PepT1 uptake and inflammatory signaling Preclinical findings do not establish human treatment efficacy
Laroui et al., 2010 Nanoparticles and a mouse colitis model Investigated delivery of KPV to the colon The engineered system is part of the intervention
Xiao et al., 2017 Functionalized nanoparticles, cell work, and mouse experiments Examined targeted delivery and inflammation-related outcomes A free-peptide vial is not the tested delivery platform

Laroui and colleagues engineered nanoparticles with a polysaccharide hydrogel approach to investigate colonic delivery. The model assessed a delivery strategy, not just the presence of three amino acids (Laroui et al., 2010).

Xiao and colleagues loaded KPV into hyaluronic acid-functionalized nanoparticles and evaluated a hydrogel-based system. Their results concerned that combined platform in the tested models. Transferring its conclusions to an ordinary KPV preparation would omit a central part of the experiment (Xiao et al., 2017).

Why delivery changes the evidence

When a paper tests peptide-loaded particles, several components can contribute to the outcome: the peptide, the carrier, its functionalization, and the way the material is released. A comparison with free peptide can help investigate those contributions, but the final system remains a different test article.

This distinction is especially important in search results. A headline may emphasize KPV while the study title and methods describe a complex delivery platform. Read the material description before attributing every result to a free-peptide preparation.

The cited work supports continued preclinical investigation. It does not, on its own, establish that a catalog KPV product treats inflammatory bowel disease in people. It also does not establish a universal route, exposure, or outcome across different models. Each extension needs evidence appropriate to that question.

Laboratory planning for Hero KPV

The supplied 5 mg and 10 mg options describe catalog quantities. They do not specify a final concentration or reproduce a nanoparticle system. Start with a validated method and determine whether the intended test article is free peptide, a formulated preparation, or a material used as part of a delivery experiment.

Review identity and quantity documentation before preparing solutions. Record the solvent, preparation conditions, and lot identifier. Use documented storage and stability information instead of assuming that a very short peptide has no handling constraints.

For uptake or signaling experiments, consider suitable vehicle and matrix controls. If studying a carrier, include comparisons that can separate carrier-associated changes from peptide-associated ones. Decide how cell viability will be assessed so a lower signaling measurement is not automatically interpreted as the intended biological effect.

Keep the analytical and biological questions distinct. Confirming a peptide’s identity helps define the experiment; it does not guarantee a particular response. Measuring a response, in turn, does not establish every proposed mechanism unless the design can distinguish them.

KPV research FAQ

What does KPV stand for?

It is the one-letter sequence abbreviation for lysine-proline-valine, or Lys-Pro-Val. Product documentation should establish the exact supplied chemical form.

What is PepT1’s role in KPV research?

The cited 2008 study investigated PepT1-mediated uptake in epithelial and immune-cell systems. Transporter context is part of interpreting those experimental responses.

Are KPV nanoparticles the same as free KPV?

No. Nanoparticles and hydrogels are additional components of a delivery system. Results from that platform should be attributed to the tested preparation.

What KPV sizes does Hero list?

The supplied catalog lists 5 mg and 10 mg. These quantities should be matched to the requirements of a documented laboratory method.

KPV. View catalog product

References

  1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. Source.
  2. Laroui H, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010. Source.
  3. Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack